ascendis pharma glp-1 receptor agonists weight management diabetes treatments Ozempic maker Novo Nordisk is working on a once-monthly weight-loss drug Understanding GLP-1 receptor agonists and
Description
34 (4), e2982 (2018)

Less common side effects may include fatigue, headaches, dizziness, or injection site reactions

[DOI] [PMC free article] [PubMed] [Google Scholar] 66.Pinheiro MM, de Souza LG, Nunes GP, et al

Intern Med J

A Phase 1, Randomized, double-blind, placebo-controlled single and multipleascending dose study of AMG 133 in subjects with obesity
